A product comprising theanine, caffeine, and CBD is disclosed. Alternatives to the specific components are also described. A product comprising theanine, pyridoxine triacetate, and CBD is also disclosed. Alternatives to the specific components are also described. In an embodiment, an oral thin film strip delivery system includes a polymer, muco-adhesive, or other component that allows the product to dissolve in the mouth.

A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.

The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

A pharmaceutical composition, a preparation and a use for treating oral mucosal wounds. The pharmaceutical composition includes a glutamine, s mucoadhesive polymer, and a slow-release polymer. The mucoadhesive polymer is charged polymer. The slow-release polymer is uncharged polymer. Based on the total weight of the pharmaceutical composition, the content of glutamine is 5% by weight to 75% by weight, the content of mucoadhesive polymer is 20% by weight to 70% by weight, and the content of slow-release polymer is 20% by weight to 70% by weight.

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent;
wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

One compound (100) according to the present invention contains silicon fine particles having a capability of generating hydrogen or aggregates of the silicon fine particles. The compound that contains the silicon fine particles or the aggregates having a capability of generating hydrogen is capable of generating hydrogen in the body of, for example, an animal that has ingested the compound. For a plant, the compound can be disposed or charged into, for example, moisture (water-containing liquid) or fertilizer to be provided to the plant, to supply the plant with hydrogen generated from the compound.

The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogenic mi-crobes that has localized on the mucocutaneous lining of the conjunctiva, mouth and nose, lung, or gastrointestinal tract. The cyclodex-trin may bind the viral particles and/or disrupt viral entry mechanisms by removing cholesterol from viral particles to reduce infectivity. Cyclodextrins also may facilitate removal of the viral cholesterol molecules, thus rendering them less viable. Cyclodextrin activity may be further enhanced when used in combination with certain minerals and/or antioxidant compounds.

Pharmaceutical compositions employing flavor entrapment to mitigate the unpleasant taste of active agents are described.

The present disclosure provides epinephrine formulations and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, methods for treating hypoglycemia, and a prophylactic method for immunotherapy, using the epinephrine formulations disclosed herein. The epinephrine formulations of the present disclosed are formulated for delivery via the oral mucosa. Epinephrine formulations of the present disclosure may further comprise citric acid to improve delivery of epinephrine through the oral mucosa. The epinephrine formulations of the present disclosure induce a robust, global sympathetic response in a subject that is disproportionate to the serum epinephrine concentration in the subject.

A non-crystallizing blend includes cannabidiol (CBD) and cannabidiolic acid (CBDA). A method of forming a non-crystallizing blend of CBD and CBDA includes obtaining a CBD isolate including at least 80% by weight CBD, obtaining a CBDA isolate including at least 80% by weight CBDA, and combining and mixing the CBD isolate and the CBDA. A method of treating a condition includes administering a therapeutically effective amount of a non-crystallizing blend of CBD and CBDA to a patient in need thereof.